A
Alyssum Therapeutics
Pioneering B cell immunotherapy to regulate immune response and treat complex diseases
About Alyssum Therapeutics
Alyssum Therapeutics is at the forefront of cancer immunology, focusing on pioneering B cell immunotherapy to regulate immune responses and treat complex diseases. The company operates in the biopharmaceutical sector, targeting complex diseases with a particular emphasis on cancer. Alyssum's business model revolves around developing next-generation targeted immunotherapies, with a strong focus on advancing patient outcomes and quality of life. The company generates revenue through the development and potential commercialization of its therapeutic candidates, such as AT 1965, which is currently under clinical trials. Alyssum serves patients with complex diseases, particularly those with hard-to-treat tumors, and actively recruits participants for its clinical trials. The team at Alyssum boasts extensive experience, having been involved with over 20 drugs on the market and multiple recent accelerated USFDA approvals. The company leverages its expertise to push the boundaries of science, aiming to transform patient lives through innovative treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $2M | $73M | FemHealth Ventures | ↗ |
| SERIES A✓Equity / VC | Oct 2024 | $15M | $58M | Accel · Navam Capital · Famy Care Ltd | ↗ |
Growth signals
Latest recorded traffic for Alyssum Therapeutics is 2K monthly website visits, up 217.5% over the last three months. Alyssum Therapeutics's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alyssum Therapeutics in the Cambridge ecosystem
The Alyssum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Accel
Navam Capital
Famy Care Ltd
FemHealth Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alyssum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alyssum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









